FDA extends probe into AstraZeneca Covid-19 vaccine – STAT
Oxford University will study if Humira is effective for treating Covid-19, the latest effort to repurpose drugs as coronavirus therapies.
Related Articles
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Pharmalittle: We’re reading about plans for generic Wegovy, cough syrup warnings, and more
Biocon is developing a generic version of Novo Nordisk’s Wegovy and is prepared to conduct a clinical trial next year if needed.
Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
BIO’s about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and…
Pharmalittle: We’re reading about Lilly’s Zepbound for sleep apnea, the FDA budget, and more
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
Pharmalittle: We’re reading about CVS and Humira biosimilars, Schumer’s broken insulin promise, and more
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week…
Pharmalittle: We’re reading about a J&J cough syrup, a Pfizer and Moderna patent suit, and more
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
Colorado lawmakers are abandoning a bill that would have required a new state board — chartered with setting caps for the cost of medicines — to…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal…
Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s…